Cancer therapeutics based on BCL-2 functional conversion

Apoptosis. 2019 Feb;24(1-2):1-2. doi: 10.1007/s10495-018-1504-5.

Authors

Martin C Pearce¹, Arnold C Satterthwait², Xiao-Kun Zhang^{2

3}, Siva Kumar Kolluri^{4

5}

Affiliations

¹ Cancer Research Laboratory, Department of Environmental & Molecular Toxicology, Oregon State University, Corvallis, OR, 97331, USA.
² Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA, 92037, USA.
³ School of Pharmaceutical Sciences, Xiamen University, Xiamen, 361005, China.
⁴ Cancer Research Laboratory, Department of Environmental & Molecular Toxicology, Oregon State University, Corvallis, OR, 97331, USA. siva.kolluri@oregonstate.edu.
⁵ Linus Pauling Institute, Oregon State University, Corvallis, OR, 97331, USA. siva.kolluri@oregonstate.edu.

PMID: 30612317
DOI: 10.1007/s10495-018-1504-5

No abstract available

MeSH terms

Animals
Apoptosis Regulatory Proteins / metabolism
Apoptosis Regulatory Proteins / physiology
Apoptosis* / genetics
Cell Survival / genetics
Humans
Inhibitor of Apoptosis Proteins / metabolism
Inhibitor of Apoptosis Proteins / physiology
Molecular Targeted Therapy / methods*
Neoplasms / drug therapy*
Neoplasms / metabolism
Neoplasms / pathology
Nuclear Receptor Subfamily 4, Group A, Member 1 / chemistry
Nuclear Receptor Subfamily 4, Group A, Member 1 / metabolism*
Oligopeptides / pharmacology
Oligopeptides / therapeutic use*
Proto-Oncogene Proteins c-bcl-2 / metabolism
Proto-Oncogene Proteins c-bcl-2 / physiology*
Tumor Burden / drug effects

Substances

Apoptosis Regulatory Proteins
BCL2 protein, human
Inhibitor of Apoptosis Proteins
NR4A1 protein, human
Nuclear Receptor Subfamily 4, Group A, Member 1
Oligopeptides
Proto-Oncogene Proteins c-bcl-2
phenylalanyl-seryl-arginyl-seryl-leucyl-histidyl-seryl-leucyl-leucine